Rhea-AI Filing Summary
Kestra Medical Technologies reports that an affiliate plans to sell 2,380 shares of common stock through Merrill Lynch on August 3, 2026 on NASDAQ, with an indicated aggregate market value of $56,551.44. These shares relate to performance share unit awards that vested on July 17, 2026 and were granted under the issuer’s equity compensation plan. The notice also lists prior sales by Timothy Moran of 4,117 shares for $93,758.64 on July 30, 2026 and 8,759 shares for $198,000.29 on July 31, 2026.
Positive
- None.
Negative
- None.
Key Figures
Planned shares to be sold: 2,380 shares Aggregate market value of planned sale: $56,551.44 Vesting date of performance share units: 07/17/2026 +4 more
Planned shares to be sold 2,380 shares Common stock to be sold through Merrill Lynch on August 3, 2026
Aggregate market value of planned sale $56,551.44 Estimated value of 2,380 shares of common stock
Vesting date of performance share units 07/17/2026 Date performance share unit awards vested into common stock
Shares sold on July 30, 2026 4,117 shares Common stock sold by Timothy Moran
Proceeds on July 30, 2026 $93,758.64 Value of 4,117 shares of common stock sold
Shares sold on July 31, 2026 8,759 shares Common stock sold by Timothy Moran
Proceeds on July 31, 2026 $198,000.29 Value of 8,759 shares of common stock sold
Key Terms
performance share unit awards, equity compensation plan, aggregate market value
equity compensation plan financial
"Granted as part of issuer equity compensation plan"
A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.
aggregate market value financial
"2380 | 56551.44 | 58602497 | 08/03/2026 | NASDAQ"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stock sale is being reported for Kestra Medical Technologies (KMTS)?
A planned sale of 2,380 shares of Kestra Medical Technologies common stock is reported, to be executed through Merrill Lynch on August 3, 2026 on NASDAQ, with an aggregate market value of $56,551.44.
Which prior Kestra Medical Technologies (KMTS) stock sales are disclosed?
The disclosure lists Timothy Moran’s sales of 4,117 shares for $93,758.64 on July 30, 2026 and 8,759 shares for $198,000.29 on July 31, 2026, both involving Kestra Medical Technologies common stock.